Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GNTA Genenta Science	$3.53 +1.9%	$3.65	$2.74 ▼ $7.28	$64.10M	0.62	4,424 shs	1,713 shs
INMB INmune Bio	$2.53 +3.3%	$3.89	$1.89 ▼ $11.64	$67.26M	0.97	2.97 million shs	527,682 shs
NRSN NeuroSense Therapeutics	$1.19 +1.7%	$1.90	$0.67 ▼ $2.60	$16.26M	1.64	430,312 shs	169,515 shs
STRO Sutro Biopharma	$0.88 +12.5%	$0.80	$0.52 ▼ $5.17	$74.43M	1.66	448,691 shs	1.31 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GNTA Genenta Science	0.00%	-5.87%	-7.02%	-17.06%	-20.96%
INMB INmune Bio	0.00%	-1.17%	+12.95%	-67.81%	-62.41%
NRSN NeuroSense Therapeutics	0.00%	-5.56%	-39.59%	-9.85%	+70.00%
STRO Sutro Biopharma	0.00%	+9.42%	+14.64%	-3.69%	-75.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GNTA Genenta Science	2.7914 of 5 stars	3.5	3.0	0.0	3.8	1.7	0.0
INMB INmune Bio	1.9951 of 5 stars	3.3	2.0	0.0	1.4	1.7	0.6
NRSN NeuroSense Therapeutics	2.3802 of 5 stars	3.5	3.0	0.0	2.3	1.7	0.0
STRO Sutro Biopharma	4.2633 of 5 stars	3.1	5.0	4.7	2.9	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GNTA Genenta Science	3.00	Buy	$25.00	609.22% Upside
INMB INmune Bio	2.57	Moderate Buy	$18.40	627.27% Upside
NRSN NeuroSense Therapeutics	3.00	Buy	$14.00	1,076.47% Upside
STRO Sutro Biopharma	2.14	Hold	$4.47	408.73% Upside

Current Analyst Ratings Breakdown

Latest NRSN, INMB, STRO, and GNTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	NRSN NeuroSense Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
8/12/2025	STRO Sutro Biopharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$4.00 ➝ $3.00
7/10/2025	NRSN NeuroSense Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
7/2/2025	INMB INmune Bio	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $8.00
7/1/2025	INMB INmune Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
7/1/2025	INMB INmune Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Outperform ➝ Sector Underperform
6/30/2025	INMB INmune Bio	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
6/16/2025	STRO Sutro Biopharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$2.00
5/19/2025	STRO Sutro Biopharma	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$1.00 ➝ $0.80

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GNTA Genenta Science	N/A	N/A	N/A	N/A	$0.74 per share	N/A
INMB INmune Bio	$50K	1,345.20	N/A	N/A	$1.09 per share	2.32
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	($0.04) per share	N/A
STRO Sutro Biopharma	$62.04M	1.20	N/A	N/A	($0.38) per share	-2.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GNTA Genenta Science	-$9.64M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	-$42.08M	-$2.48	N/A	N/A	N/A	N/A	-120.62%	-92.94%	10/30/2025 (Estimated)
NRSN NeuroSense Therapeutics	-$10.21M	-$0.54	N/A	∞	N/A	N/A	N/A	-445.40%	9/29/2025 (Estimated)
STRO Sutro Biopharma	-$227.46M	-$2.53	N/A	N/A	N/A	-201.32%	-852.70%	-58.67%	N/A

Latest NRSN, INMB, STRO, and GNTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	Q2 2025	INMB INmune Bio	-$0.37	-$0.34	+$0.03	-$1.05	$0.00 million	N/A
8/7/2025	Q2 2025	STRO Sutro Biopharma	-$0.39	-$0.14	+$0.25	-$0.14	$14.55 million	$63.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GNTA Genenta Science	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
NRSN NeuroSense Therapeutics	N/A	N/A	N/A	N/A	N/A
STRO Sutro Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GNTA Genenta Science	N/A	6.89	6.89
INMB INmune Bio	N/A	4.20	2.64
NRSN NeuroSense Therapeutics	N/A	0.71	2.21
STRO Sutro Biopharma	N/A	3.12	2.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GNTA Genenta Science	15.13%
INMB INmune Bio	12.72%
NRSN NeuroSense Therapeutics	1.04%
STRO Sutro Biopharma	96.99%

Insider Ownership

Company	Insider Ownership
GNTA Genenta Science	28.99%
INMB INmune Bio	35.70%
NRSN NeuroSense Therapeutics	27.40%
STRO Sutro Biopharma	3.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GNTA Genenta Science	7	18.29 million	12.99 million	Not Optionable
INMB INmune Bio	10	26.59 million	17.09 million	Optionable
NRSN NeuroSense Therapeutics	10	13.67 million	9.92 million	Not Optionable
STRO Sutro Biopharma	240	84.77 million	81.72 million	Optionable

NRSN, INMB, STRO, and GNTA Headlines

Recent News About These Companies

Sutro Biopharma (STRO) Gets a Buy from Truist Financial

August 14 at 10:10 AM | theglobeandmail.com

Sutro Biopharma (NASDAQ:STRO) Price Target Cut to $3.00 by Analysts at Wells Fargo & Company

August 14 at 2:55 AM | americanbankingnews.com

Wells Fargo & Company Cuts Sutro Biopharma (NASDAQ:STRO) Price Target to $3.00

August 13, 2025 | marketbeat.com

Sutro Biopharma price target lowered to $3 from $4 at Wells Fargo

August 12, 2025 | msn.com

Sutro Biopharma (NASDAQ:STRO) Rating Increased to Hold at Wall Street Zen

August 11, 2025 | americanbankingnews.com

Sutro Biopharma (NASDAQ:STRO) Upgraded at Wall Street Zen

August 10, 2025 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Sutro Biopharma (STRO) and Relay Therapeutics (RLAY)

August 9, 2025 | theglobeandmail.com

Sutro Biopharma, Inc.: Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights

August 8, 2025 | finanznachrichten.de

Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $6.11 Consensus PT from Brokerages

August 8, 2025 | americanbankingnews.com

Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Beats Revenue Estimates

August 7, 2025 | zacks.com

Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights

August 7, 2025 | globenewswire.com

Sutro Biopharma (STRO) Expected to Announce Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of "Hold" from Analysts

August 5, 2025 | marketbeat.com

Sutro Biopharma (NASDAQ:STRO) Trading 0.6% Higher - Time to Buy?

August 3, 2025 | marketbeat.com

Sutro Biopharma, Inc.: Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug Conjugates

July 24, 2025 | finanznachrichten.de

Here's Why Sutro Biopharma (NASDAQ:STRO) Must Use Its Cash Wisely

July 23, 2025 | finance.yahoo.com

Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug Conjugates

July 23, 2025 | finance.yahoo.com

Sutro Biopharma upgraded to Overweight from Neutral at Piper Sandler

June 16, 2025 | msn.com

Sutro Biopharma Appoints Greg Chow as Chief Financial Officer

June 2, 2025 | finance.yahoo.com

Sutro Biopharma, Inc.: Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

May 9, 2025 | finanznachrichten.de

Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates

May 8, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NRSN, INMB, STRO, and GNTA Company Descriptions

Genenta Science NASDAQ:GNTA

$3.52 +0.07 (+1.88%)

As of 08/15/2025 03:50 PM Eastern

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

INmune Bio NASDAQ:INMB

$2.53 +0.08 (+3.27%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.48 -0.05 (-1.94%)

As of 08/15/2025 07:56 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

NeuroSense Therapeutics NASDAQ:NRSN

$1.19 +0.02 (+1.71%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.20 +0.01 (+0.42%)

As of 08/15/2025 07:55 PM Eastern

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

Sutro Biopharma NASDAQ:STRO

$0.88 +0.10 (+12.55%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$0.89 +0.01 (+1.37%)

As of 08/15/2025 07:43 PM Eastern

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time